Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus
24-Nov-2014 -
Autifony Therapeutics Limited, which is pioneering the development of novel pharmaceutical treatments for hearing disorders, announced that it has initiated a Phase IIa study in tinnitus subjects with its lead compound AUT00063. This proof of concept study (called the QUIET-1 study, QUest In ...
phase IIa studies
tinnitus